2.1
Givinostat (Duvyzat, ITF Pharma UK) is indicated for 'the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older'.
2 Information about givinostat
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for givinostat.
Price
2.3
The price of givinostat is £13,846 per 140 ml of 8.86 mg/ml oral suspension (excluding VAT, BNF online July 2025).
2.4
The company has a commercial arrangement. This makes givinostat available to the NHS for this indication with a discount. The size of the discount is commercial in confidence.
Sustainability
2.5
For information, ITF Pharma UK did not disclose its Carbon Reduction Plan for UK carbon emissions.